Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...
PureTech Health has obtained approval from the US Food and Drug Administration (FDA) for KarXT to treat schizophrenia in ...
From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...
The medication is the first in decades to have a different mode of action than do current drugs, achieving better symptom ...
After more than three decades, schizophrenia patients have a new treatment option. The US FDA has approved a drug, known as ...
Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults ...
Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than antipsychotic treatments ...
This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...
Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; ...
Nine years on from securing $3.84 million for a phase I clinical trial to test the formulation, with results showing it ...
KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback